Table 3.

Final histologic classification in the pathology report.

	Total (n=259)	Benign (n=149)	indeterminate (n=110)
Benign, n (%)	140 (54.1%/100%)	91 (61.1%/100%)	49 (44.5%/100%)
Adenomatous hyperplasia	65 (25.1%/46.4%)	48 (32.2%/52.8%)	17 (15.4%/34.7%)
Follicular adenoma	54 (20.8%/38.6%)	33 (22.1%/36.3%)	21 (7.4%/15.1%)
Oncocytic cell adenoma	20 (7.4%/19.3%)	9 (6.0%/9.9%)	11 (10.0%/22.5%)
Lymphocytic thyroiditis	1 (0.3%/0.7%)	1 (0.7%/1.1%)	0 (0%)
Malignancy, n (%)	119 (45.9%/100%)	58 (38.9%/100%)	61 (55.5%/100%)
NIFTP	10 (3.9%/8.4%)	5 (3.4%/8.6%)	5 (4.5%/8.2%)
PTC	75 (29.0%/63.0%)	36 (24.2%/62.1%)	39 (35.5%/63.9%)
Follicular	22 (8.5%/18.5%)	11 (7.4%/19.0%)	11 (10.0%/18.0)
Oncocytic	5 (1.9%/4.2%)	1 (0.7%/1.7%)	4 (3.6%/6.6%)
Poorly differentiated	7 (2.7%/5.9%)	5 (3.4%/8.6%)	2 (1.8%/3.3%)